Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lotronex Withdrawal Reflects Danger Of First-To-Market Products, GSK Says

Executive Summary

The withdrawal of Lotronex indicates the risk of launching the first product for a new indication in the current regulatory environment, GlaxoSmithKline Senior VP-New Product Development James Palmer maintained during a securities analysts meeting in London Feb. 22.

You may also be interested in...



FDA Cancer Chief Pazdur Backed By MD Anderson, Not PhRMA, For Commissioner

FDA Oncology Drug Products Division Director Richard Pazdur, MD, is among the candidates who have been asked to interview for the FDA commissioner position.

FDA Cancer Chief Pazdur Backed By MD Anderson, Not PhRMA, For Commissioner

FDA Oncology Drug Products Division Director Richard Pazdur, MD, is among the candidates who have been asked to interview for the FDA commissioner position.

Pfizer, PhRMA See Signs Of Drug Approval "Slowdown" At FDA

Pfizer believes that several of its pending products have been delayed by an "across-the-board" slowdown in FDA approvals, CEO Henry McKinnell told investors during the company's Jan. 24 quarterly conference call.

Related Content

UsernamePublicRestriction

Register

PS037400

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel